Further investigation of the mechanism of NAP1L5 indicated that NAP1L5 overexpression inhibited the AD-like pathological characteristics through the GSK3B/Wnt/β-Catenin signaling pathway, which could be mediated by AQP1. Here, NAP1L5 is linked to Alzheimer disease.